Sanchez-Bilboa at al. IV vs SC tocilizumab in 471 GCA patients. Equal efficacy. The authors report more adverse events with IV but actually this was purely due to longer follow up and per patient years it was the same. @RheumNow #EULAR2022 POS0272 https://t.co/2h7iIkMxjW